持续时间的抗血小板药物药物洗脱支架的研究

(每日健康)——接受药物洗脱支架的病人,双重抗血小板治疗可以安全地停止在第一年,据9月19日在网上发表的两项研究美国心脏病学会杂志》上。

在第一项研究中,Ignacio Ferreira-Gonzalez,医学博士,Ph.D., from Vall d'Hebron Hospital in Barcelona, Spain, and colleagues conducted a study involving 1,622 patients undergoing drug-eluting stent implantation. The patients were assessed at regular intervals up to a year post-implantation. During that time, 10.6 percent interrupted at least one antiplatelet drug; 64.5 percent of the interruptions were temporary. The researchers found that the rate of major cardiac events was similar in patients who continued or interrupted treatment.

在第二项研究中,Byeong-Keuk金,医学博士,from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues randomly assigned 2,117 patients with coronary artery stenosis to receive a zotarolimus-eluting stent with three months of dual抗血小板治疗或其他药物洗脱支架与12个月的双重抗血小板治疗。研究人员发现,两组有相似的主要复合终点的几率心血管死亡,心肌梗死支架血栓形成,目标或血管血管再生,或出血一年在每组(4.7%)。

”新一代药物洗脱支架,六个月的双重抗血小板治疗可能就足够了,三个月不完全异乎寻常的低风险组,“Bernhard Witzenbichler,医学博士,从Charite-Campus本杰明·富兰克林在柏林,在社论中写道。“然而,病人——和device-related标准安全允许双重抗血小板治疗早期撤军或中断还有待确定。”

Ferreira-Gonzalez研究部分由百时美施贵宝;两位作者披露金融与毒品和设备公司。两位作者金研究披露金融关系美敦力公司。

版权©2012每日健康。保留所有权利。